OMAHA, Neb. and MOUNTAIN VIEW, CA (January 26, 2016) — Transgenomic, Inc. (NASDAQ: TBIO) today announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday at the Personalized Medicine World Conference. In his talk, Dr. Legendre highlighted how Transgenomic’s versatile and powerful Multiplexed ICE COLD-PCR™ (MX-ICP) technology enables personalized medicine R&D, exemplified by its utility for stratification of clinical study patients in partnership with Transgenomic’s pharmaceutical and biotechnology clients. In addition, the exceptional accuracy of MX-ICP and its ability to enable use of liquid biopsies are supporting the rapidly growing use of personalized and precision medicine strategies in routine clinical practice.

In his talk, Dr. Legendre described how MX-ICP delivers unbiased enrichment of gene regions that allows determination of all point mutations and insertions/deletions. He noted that the ability of MX-ICP to efficiently detect genetic alterations down to 0.01% in blood and tissue samples and to increase the sensitivity of almost all downstream analysis platforms serve to make efficient detection of mutations feasible and practical for most laboratories. And the multiplexed format of MX-ICP allows sensitive detection and monitoring of all genetic alterations in multiple targets using a single DNA sample.

MX-ICP can currently be accessed for research use via Transgenomic’s Biomarker Discovery service and its ICEme™ kits, and for diagnostic use through its CLIA laboratory mutation detection tests.

Dr. Legendre commented, “MX-ICP has the combination of ultra-high sensitivity and platform and workflow flexibility needed to make personalized medicine a practical reality. The launches last year of our MX-ICP-based Biomarker Discovery service, our ICEme kits for researchers and our growing portfolio of CLIA tests for mutation detection and monitoring in lung and colorectal cancer provide researchers and clinicians a variety of ways to access the benefits of this important new technology.”

For information on Transgenomic’s Biomarker Discovery services, click here. For information about its ICEme kits, click here. For information about its CLIA cancer tests, click here.

Multiplexed ICE COLD-PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available. ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.

Dr. Legendre presented, “The Use of Multiplexed ICE COLD-PCR Coupled to Multiple Downstream Analysis Platforms” at the Personalized Medicine World Conference being held in Mountain View, CA, January 24-27, 2016.

About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ and unique genetic tests provided through its Patient Testing business. Transgenomic also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 15, 2015. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


BLL Partners LLC
Barbara Lindheim

Transgenomic Investor Relations